Kainos Laboratories

Kainos Laboratories EV/FCF

Delisted

The EV/FCF (Enterprise Value to Free Cash Flow) of Kainos Laboratories (4556.T) as of Oct 29, 2026 is 10.45. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 19.78 — a change of -47.15% (lower).

EV/FCF

10.45

YoY

-47.15%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Kainos Laboratories is 2025 10.45 . EV/FCF (Enterprise Value to Free Cash Flow) of Kainos Laboratories was 2024 19.78 . It decreases by -47.15% lower compared to the previous year.

The Kainos Laboratories EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
54.59 JPY
Jan 1, 2019
31.44 JPY
Jan 1, 2020
13.45 JPY
Jan 1, 2021
15.61 JPY
Jan 1, 2022
16.41 JPY
Jan 1, 2023
13.51 JPY
Jan 1, 2024
19.78 JPY
Jan 1, 2025
10.45 JPY
The Kainos Laboratories EV/FCF history
YEAREV/FCFYoY
10.45-47.15%
19.78+46.43%
13.51-17.68%
16.41+5.10%
15.61+16.08%
13.45-57.21%
31.44-42.42%
54.59+80.46%
30.25-55.34%
67.74+156.64%
26.39-5.33%
27.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

EV/FCF (Enterprise Value to Free Cash Flow) of Kainos Laboratories is 10.45 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Kainos Laboratories changed from 19.78 to 10.45, representing a -47.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Kainos Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Kainos Laboratories

All Key Metrics — Kainos Laboratories